RDHL - RedHill Biopharma Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
10.94
+0.26 (+2.44%)
As of 10:55AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close10.68
Open10.69
Bid10.95 x 900
Ask10.98 x 900
Day's Range10.62 - 11.06
52 Week Range4.30 - 11.25
Volume100,474
Avg. Volume122,452
Market Cap238.06M
Beta1.53
PE Ratio (TTM)N/A
EPS (TTM)-2.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.17
Trade prices are not sourced from all markets
  • RedHill Gets Two New Patents for Crohn's Disease Candidate
    Zacks11 days ago

    RedHill Gets Two New Patents for Crohn's Disease Candidate

    RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.

  • RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%
    Zacks14 days ago

    RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%

    RedHill Biopharma (RDHL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • GlobeNewswire14 days ago

    RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., July 02, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal (GI) diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) and an Intention to Grant from the European Patent Office (EPO) for two new patents covering RHB-104, expected to be valid until at least February 5, 2029, once granted. The development of RHB-104 for Crohn’s disease is based on the hypothesis that Crohn’s disease is caused by Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients.

  • ACCESSWIRE18 days ago

    Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product

    SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), today announced that it has entered into an agreement (the Agreement) with RedHill Biopharma Ltd. (RedHill) (RDHL), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, to establish a U.S. co-promotion program for Mytesi® (crofelemer 125 mg delayed-release tablets), Napo's FDA-approved drug, for the current approved indication. Mytesi is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

  • GlobeNewswire18 days ago

    RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®

    RedHill has been granted the exclusive right to co-promote Mytesi ® in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by ...

  • RedHill Biopharma (RDHL): Moving Average Crossover Alert
    Zacks18 days ago

    RedHill Biopharma (RDHL): Moving Average Crossover Alert

    RedHill Biopharma Ltd. (RDHL) is looking like an interesting pick from a technical perspective

  • RedHill Biopharma (RDHL) Shares March Higher, Can It Continue?
    Zacks28 days ago

    RedHill Biopharma (RDHL) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in RedHill Biopharma Ltd. (RDHL)

  • GlobeNewswirelast month

    Factors of Influence in 2018, Key Indicators and Opportunity within BiondVax Pharmaceuticals, MercadoLibre, 1-800 FLOWERS.COM, Redhill Biopharma, Mountain Province Diamonds, and Rhythm Pharmaceuticals — New Research Emphasizes Economic Growth

    NEW YORK, June 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BiondVax ...

  • Is RedHill's experimental Ebola treatment on FDA fast track?
    American City Business Journals2 months ago

    Is RedHill's experimental Ebola treatment on FDA fast track?

    With a new patent in hand, Tel-Aviv-based RedHill Biopharma – which is growing its U.S. commercial operations from Raleigh – is looking to advance an experimental treatment for Ebola virus.  RedHill (Nasdaq: RDHL) said Tuesday that the United States Patent and Trademark Office has issued a patent covering the experimental treatment until 2035.  RedHill has completed a proof-of-concept study looking at survival outcomes and disease severity through a research collaboration with the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. When it comes to other pharmaceutical companies working in the space, most are focused on developing a vaccine for people at risk of contracting Ebola.

  • GlobeNewswire2 months ago

    RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018

    TEL-AVIV, Israel and RALEIGH, N.C., May 30, 2018-- RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces New U.S. Patent for its Experimental Ebola Therapy

    TEL-AVIV, Israel and RALEIGH, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering RedHill’s proprietary experimental therapy for the treatment of Ebola virus disease. As part of RedHill’s research collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), the Company successfully completed a proof-of-concept study to evaluate its proprietary experimental therapy for the treatment of Ebola virus disease.

  • GlobeNewswire2 months ago

    RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn’s Disease on May 15

    TEL-AVIV, Israel and RALEIGH, N.C., May 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that it will host a webcast for the investment community on RHB-104 and the first Phase III study with RHB-104 for Crohn’s disease (MAP US), tomorrow, Tuesday, May 15, at 8:00 a.m. EDT. Members of RedHill’s executive team will be joined by key opinion leaders who will discuss RHB-104, the MAP US study, Crohn’s disease, the current treatment landscape and potential market.

  • GlobeNewswire2 months ago

    RedHill Biopharma Reports First Quarter 2018 Financial Results

    Top-line results from Phase III study with RHB-104 for Crohn’ s disease expected in approximately 3 months Top-line results from confirmatory Phase III study with TALICIA ® for H. pylori infection expected ...

  • Durham pharma eyes potential approval of drug in roughly $5B market
    American City Business Journals2 months ago

    Durham pharma eyes potential approval of drug in roughly $5B market

    RedHill Biopharma has its sights set on potential approval of a drug in a market of roughly $5 billion.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., May 07, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that the last patient enrolled in the first Phase III study with RHB-104 for Crohn’s disease (the MAP US study) has completed 26 weeks of treatment for primary endpoint evaluation. Top-line results are expected to be announced in approximately three months.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection

    Approximately 70% of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA ® for H. pylori infection RedHill expects to complete enrollment ...

  • GlobeNewswire2 months ago

    RedHill Biopharma to Host First Quarter 2018 Financial Results Conference Call on May 8, 2018

    TEL-AVIV, Israel and RALEIGH, N.C., May 01, 2018-- RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...

  • RedHill revenues up 31 percent in Q4
    American City Business Journals3 months ago

    RedHill revenues up 31 percent in Q4

    RedHill Biopharma's revenues continue to climb after starting U.S. promotional activities for two gastrointestinal products in June and September.

  • Reuters3 months ago

    BRIEF-Swire Pacific Announces Sale Of Residential Unit For HK$120 Million By Redhill Properties

    April 9 (Reuters) - Swire Pacific Ltd: * TO SELL RESIDENTIAL UNIT FOR HK$120 MILLION * CO EXPECTED TO RECORD ATTRIBUTABLE GAIN ON DISPOSAL ABOUT HK$29.1 MILLION * PROPERTY SALE CARRIED OUT THROUGH PROPERTY ...

  • Reuters4 months ago

    Sainsbury's needs year's notice to act on post-Brexit trade deal

    Sainsbury's (SBRY.L), Britain's No.2 supermarket group, needs at least a year's notice to figure out how it would deal with new European Union-UK trading arrangements that would come into play when the Brexit transition period ends, its boss said on Tuesday. Last week, EU leaders approved a transition period to help business adapt after Brexit, allowing talks to start next month on the bloc's future trading relationship with Britain. "Effectively the can's been kicked down the road by 21 months," Sainsbury's Chief Executive Mike Coupe told reporters during a tour of its store in Redhill, southern England.